Quarterly report pursuant to Section 13 or 15(d)

Document and Entity Information

v3.23.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2023
Aug. 01, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Trading Symbol IKT  
Entity Registrant Name INHIBIKASE THERAPEUTICS, INC.  
Entity Central Index Key 0001750149  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Shell Company false  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity File Number 001-39676  
Entity Current Reporting Status Yes  
Entity Tax Identification Number 26-3407249  
Entity Address, Address Line One 3350 Riverwood Parkway SE  
Entity Address, Address Line Two Suite 1900  
Entity Address, City or Town Atlanta  
Entity Address, State or Province GA  
Entity Address, Postal Zip Code 30339  
City Area Code 678  
Local Phone Number 392-3419  
Entity Interactive Data Current Yes  
Title of 12(b) Security Common Stock, $0.001 par value  
Security Exchange Name NASDAQ  
Entity Incorporation, State or Country Code DE  
Document Quarterly Report true  
Document Transition Report false  
Entity Common Stock, Shares Outstanding   5,348,326